Want to see CV full AI Analyst Report?
CV Stock Chart & Stats
$5.99
$0.12(1.85%)
At close: 4:00 PM EDT
$5.99
$0.12(1.85%)
Day’s Range― - ―
52-Week Range$4.38 - $15.37
Previous Close$6.74
Volume83.71K
Average Volume (3M)222.97K
Market Cap
$328.31M
Enterprise Value$370.14M
Total Cash (Recent Filing)$9.08M
Total Debt (Recent Filing)$687.00K
Price to Earnings (P/E)―
Beta-1.44
Next Earnings
Nov 12, 2026EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.63
Shares Outstanding53,210,358
10 Day Avg. Volume232,869
30 Day Avg. Volume222,975
Financial Highlights & Ratios
PEG Ratio-0.77
Price to Book (P/B)37.78
Price to Sales (P/S)36.96
P/FCF Ratio-21.83
Enterprise Value/Market Cap1.13
Enterprise Value/Revenue26.65
Enterprise Value/Gross Profit52.37
Enterprise Value/Ebitda-12.50
Forecast
1Y Price Target
$9.00Price Target Upside50.25% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.56
Revenue Forecast (FY)$14.72M
Bulls Say, Bears Say
Bulls Say
Growing Capsule UtilizationRising capsule shipments and cumulative patient use indicate expanding utilization of CapsoVision’s diagnostic platform. A growing installed user base can support recurring procedure-driven capsule revenue, strengthen clinical familiarity, and improve the company’s ability to expand within hospital and GI-practice networks.
FDA-Cleared Integrated AI OfferingU.S. clearance removes a major commercialization barrier for an AI tool embedded in CapsoVision’s existing workflow. Integration with CapsoView and CapsoCloud can enhance the platform’s value to clinicians, support reading efficiency, and improve competitive positioning as capsule endoscopy adoption develops.
Commercial Scale And Intellectual PropertyExpansion across larger healthcare systems, a dedicated direct sales organization, and a substantial U.S. patent portfolio provide foundations for broader commercialization. These assets can support customer acquisition, protect differentiated technology, and create a more durable market position as the product portfolio expands.
Bears Say
Persistent Cash Burn And Deep LossesMaterial recurring cash burn and very large net losses weaken financial self-sufficiency despite strong revenue growth. Unless operating performance improves substantially, the company may need continued external capital to fund commercial operations and development, reducing flexibility and increasing financing risk over the next several quarters.
Margin And Pricing PressureLower gross margin and average selling price show that unit growth is not fully translating into improved economics. Persistent competitive pricing and tariff-related cost pressure could limit contribution from additional procedures, constrain reinvestment capacity, and delay the path toward sustainable profitability.
High Operating Costs And Equity Funding DependenceRapidly rising operating expenses increase the revenue scale required to reach profitability, particularly while the company funds product and clinical development. Reliance on equity offerings supplies capital but can dilute existing shareholders and signals that internal cash generation is not yet sufficient for planned expansion.
CapsoVision, Inc. News
CV FAQ
What was CapsoVision, Inc.’s price range in the past 12 months?
CapsoVision, Inc. lowest stock price was $4.38 and its highest was $15.37 in the past 12 months.
What is CapsoVision, Inc.’s market cap?
CapsoVision, Inc.’s market cap is $328.31M.
When is CapsoVision, Inc.’s upcoming earnings report date?
CapsoVision, Inc.’s upcoming earnings report date is Nov 12, 2026 which is in 38 days.
How were CapsoVision, Inc.’s earnings last quarter?
CapsoVision, Inc. released its earnings results on Aug 13, 2026. The company reported -$0.15 earnings per share for the quarter, missing the consensus estimate of -$0.13 by -$0.02.
Is CapsoVision, Inc. overvalued?
According to Wall Street analysts CapsoVision, Inc.’s price is currently Undervalued.
Does CapsoVision, Inc. pay dividends?
CapsoVision, Inc. does not currently pay dividends.
What is CapsoVision, Inc.’s EPS estimate?
CapsoVision, Inc.’s EPS estimate is -0.15.
How many shares outstanding does CapsoVision, Inc. have?
CapsoVision, Inc. has 53,210,358 shares outstanding.
What happened to CapsoVision, Inc.’s price movement after its last earnings report?
CapsoVision, Inc. reported an EPS of -$0.15 in its last earnings report, missing expectations of -$0.13. Following the earnings report the stock price went down -4.86%.
Which hedge fund is a major shareholder of CapsoVision, Inc.?
Currently, no hedge funds are holding shares in CV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CapsoVision, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$9.00 (50.25% Upside)
$9.00 (50.25% Upside)
Blogger Sentiment
Bullish
CV Sentiment 100%
Sector Average 65%
Sector Average 65%
Insider Transactions
Bought Shares
Worth $16.0M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
28.54%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
94.50%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
CapsoVision, Inc.
CapsoVision, Inc., a medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. The company offers CapsoCam Plus, a capsule endoscopy system for visualization of the small bowel mucosa in adults and children aged 2 years and above; and CapsoCam Colon for visualization of the colon and detection and measurement of polyps, as well as develops CapsoColon 3D for large intestines (colon). It also provides CapsoCloud cloud-based software-as-a-service ecosystem as an off-premises video access and download solution; CapsoView, a data access reading device for viewing capsule videos; CapsoAccess, a Capsule data access system; and CapsoRetrieve, a retrieval kit to recover the capsule using a magnetic wand, as well as capsule video reading services. The company serves gastrointestinal medical practices, clinics, and hospitals. It sells its products to distributor customers who resell products. The company was formerly known as Capso Vision Inc. and changed its name to CapsoVision, Inc. in May 2016. CapsoVision, Inc. was incorporated in 2005 and is headquartered in Saratoga, California.
CV Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mix of constructive commercial and product-development progress — including double-digit unit and patient-growth, the international launch of AI Highlights, meaningful pipeline milestones, and initiatives to secure financing — alongside notable near-term challenges such as margin compression, a decline in average selling price, a substantial increase in operating expenses, competitive and tariff pressures, and regulatory/timing uncertainty for U.S. clearance and product submissions.View all CV earnings summariesCV Stock 12 Month Forecast
Average Price Target
$9.00
▲(50.25% Upside)
Technical Analysis
Ownership Overview
8.93% Insiders
2.98% Mutual Funds
0.02% Other Institutional Investors
83.17% Public Companies and
Individual Investors